Compare · INBS vs MDLN
INBS vs MDLN
Side-by-side comparison of Intelligent Bio Solutions Inc. (INBS) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INBS and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 7735.1x INBS ($5.7M).
- Over the past year, INBS is down 86.2% and MDLN is down 17.1% - MDLN leads by 69.2 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 3 for INBS).
- MDLN has more recent analyst coverage (25 ratings vs 0 for INBS).
PerformanceINBS-60.95%MDLN-17.07%
2025-12-17+0.00%2026-06-08
- Company
- Intelligent Bio Solutions Inc.
- Medline Inc.
- Price
- $2.33-3.11%
- $33.80+0.58%
- Market cap
- $5.7M
- $44.40B
- 1M return
- +1.74%
- -19.55%
- 1Y return
- -86.22%
- -17.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2025
- News (4w)
- 3
- 20
- Recent ratings
- 0
- 25
Latest INBS
- Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
- SEC Form SCHEDULE 13G filed by Intelligent Bio Solutions Inc.
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Intelligent Bio Solutions Inc.
- Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified
- Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)